Expertise in
12
conditions

Dr. Michael T. Schweizer

Oncology
The Association Of University Physicians
825 Eastlake Ave E, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
The Association Of University Physicians
825 Eastlake Ave E, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Schweizer is an Oncologist in Seattle, Washington. Dr. Schweizer is highly rated in 12 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, Hormone Replacement Therapy (HRT), and Orchiectomy. Dr. Schweizer is currently accepting new patients.

His clinical research consists of co-authoring 126 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
University Of Washington Medical Ctr
Languages Spoken
English
Castilian
French
Mandarin
Spanish
Vietnamese
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Cox Health
  • EPO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
825 Eastlake Ave E, Seattle, WA 98109
Other Locations
THE ASSOCIATION OF UNIVERSITY PHYSICIANS
1959 Ne Pacific St, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: ARX517 Anti-PSMA AS269-Conjugated Monoclonal Antibody
Study Phase: Phase 1
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
Bipolar Androgen Therapy Plus Olaparib in Patient With Castration-Resistant Prostate Cancer
Bipolar Androgen Therapy Plus Olaparib in Patient With Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: September 29, 2025
Intervention Type: Other, Drug
Study Drugs: Olaparib, Testosterone Enanthate, Testosterone Cypionate
Study Phase: Phase 2
Durvalumab (MEDI4736) and Olaparib (AZD2281) for Treatment of Biochemically Recurrent Prostate Cancer in Men Predicted to Have a High Neoantigen Load: A Multicenter Pilot Study
Durvalumab (MEDI4736) and Olaparib (AZD2281) for Treatment of Biochemically Recurrent Prostate Cancer in Men Predicted to Have a High Neoantigen Load: A Multicenter Pilot Study
Enrollment Status: Terminated
Publish Date: August 11, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Durvalumab, Olaparib
Study Phase: Phase 2
Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic Signature
Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic Signature
Enrollment Status: Terminated
Publish Date: January 01, 2025
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Phase 2
Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer
Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer
Enrollment Status: Terminated
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Enzalutamide, Erdafitinib
Study Phase: Phase 2
A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: August 21, 2023
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Fludarabine, Anakinra, Dual PSMA-Specific/TGFbeta-Resistant CAR-T Cells
Study Phase: Phase 1
ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer
ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer
Enrollment Status: Terminated
Publish Date: August 03, 2023
Intervention Type: Drug, Biological
Study Drugs: Atezolizumab, Cyclophosphamide, Fludarabine, MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells, PD1 Inhibitor
Study Phase: Phase 1/Phase 2
An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)
An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)
Enrollment Status: Completed
Publish Date: July 14, 2023
Intervention Type: Drug
Study Drug: ESK981
Study Phase: Phase 2
A Phase 2 Study of Apalutamide in Active Surveillance Patients
A Phase 2 Study of Apalutamide in Active Surveillance Patients
Enrollment Status: Terminated
Publish Date: February 09, 2023
Intervention Type: Other, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy
Enrollment Status: Completed
Publish Date: January 13, 2022
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Castration-Resistant Prostate Cancer
A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: April 18, 2018
Intervention Type: Other, Drug
Study Phase: Phase 1
Durvalumab (MEDI4736) in Hypermutated Metastatic Castration-Resistant Prostate Cancer
Durvalumab (MEDI4736) in Hypermutated Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Withdrawn
Publish Date: January 17, 2018
Intervention Type: Biological, Other
Study Phase: Phase 2
View 13 Less Clinical Trials

126 Total Publications

Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer.
Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer.
Journal: JCO precision oncology
Published: September 19, 2025
Similar Doctors
Expertise in
23
conditions
Dr. Ajay K. Gopal
Oncology
Expertise in
23
conditions
Dr. Ajay K. Gopal
Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Castilian, Hindi, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Ajay Gopal is an Oncologist in Seattle, Washington. Dr. Gopal is highly rated in 23 conditions, according to our data. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and B-Cell Lymphoma. Dr. Gopal is currently accepting new patients.

Expertise in
9
conditions
Dr. Petros D. Grivas
Oncology
Expertise in
9
conditions
Dr. Petros D. Grivas
Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, German, Greek, Italian, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Petros Grivas is an Oncologist in Seattle, Washington. Dr. Grivas is highly rated in 9 conditions, according to our data. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Endoscopy. Dr. Grivas is currently accepting new patients.

Expertise in
13
conditions
Dr. Bart L. Scott
Oncology
Expertise in
13
conditions
Dr. Bart L. Scott
Oncology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (1.9 miles away)
206-598-4333
Languages Spoken:
English, Arabic, Mandarin, Sindhi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Bart Scott is an Oncologist in Seattle, Washington. Dr. Scott is highly rated in 13 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Leukemia, and Bone Marrow Aspiration. Dr. Scott is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schweizer's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile